{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:41:14Z","timestamp":1777642874832,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.leukres.2010.04.010","type":"journal-article","created":{"date-parts":[[2010,6,4]],"date-time":"2010-06-04T08:32:38Z","timestamp":1275640358000},"page":"80-86","source":"Crossref","is-referenced-by-count":16,"title":["Pegylated IFN-\u03b12a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone"],"prefix":"10.1016","volume":"35","author":[{"given":"Franck E.","family":"Nicolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Hayette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Legros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Maloisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Tulliez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Guerci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pr\u00e9bet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Rigal-Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaddour","family":"Chabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Magaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Paillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Pivot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.04.010_bib1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.010_bib2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.010_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.010_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(03)14182-7","article-title":"Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa","volume":"362","author":"Marin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2010.04.010_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.010_bib7","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.04.010_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/10428190601175393","article-title":"Phase II, randomized multicenter, comparative study of peginterferon-(-2a (40KD) (Pegasys\u00ae) versus interferon (-2a (Roferon\u00ae-A) in patients with treatment-naive chronic-phase chronic myelogenous leukemia","volume":"48","author":"Lipton","year":"2007","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.leukres.2010.04.010_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.leu.2403217","article-title":"Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study","volume":"18","author":"Michallet","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.010_bib11","first-page":"870","article-title":"Polyethylene glycol interferon-(2b alone or in combination with low-dose AraC in patients newly diagnosed with chronic myeloid leukemia","volume":"89","author":"Cervantes","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.04.010_bib12","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.010_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.leukres.2005.02.006","article-title":"Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients","volume":"29","author":"Hayette","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.04.010_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.leukres.2010.04.010_bib16","first-page":"89","article-title":"Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia","volume":"1","author":"Ebos","year":"2002","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.010_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2003-08-2695","article-title":"Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia","volume":"104","author":"Legros","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib18","first-page":"345a","article-title":"Interferon-alpha augments the apoptotic effect of STI571 in Ph+-blastic crisis cell lines by inducing trail and Fas (CD95\/Apo1)","volume":"96","author":"Barteneva","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib19","first-page":"98a","article-title":"Response of STI571-resistant cell lines to other chemotherapeutic drugs and signal transduction inhibitors","volume":"96","author":"Tipping","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib20","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib21","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","article-title":"Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells","volume":"96","author":"Thiesing","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib22","first-page":"846a","article-title":"PEGIntron and STI 571 Evaluation Study (PISCES) in chronic phase chronic myeloid leukemia","volume":"98","author":"O\u2019Brien","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib23","first-page":"164a","article-title":"Imatinib (Glivec) and pegylated interferon alpha2a (Pegasys) Phase I\/II conbination study in chronic phase chronic myelogenous leukemia (CML)","volume":"100","author":"Hochhaus","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib24","first-page":"846a","article-title":"Preliminary evaluation of the combination of Imatinib Mesylate (Gleevec) in combination with low-dose interferon-alpha for the treatment of chronic phase CML","volume":"98","author":"O\u2019Dwyer","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib25","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2165\/00003495-200161150-00013","article-title":"Peginterferon-(-2a (40kD): a review of its use in the management of chronic hepatitis C","volume":"61","author":"Perry","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.leukres.2010.04.010_bib26","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnci\/95.6.437","article-title":"Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis","volume":"95","author":"von Marschall","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2010.04.010_bib28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2004-07-2909","article-title":"The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications","volume":"105","author":"Podar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib30","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.010_bib31","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.010_bib32","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","article-title":"Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia","volume":"104","author":"Baccarani","year":"2004","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610002146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610002146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T11:02:25Z","timestamp":1591354945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610002146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0145212610002146"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.04.010","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}